CNS Drugs

, Volume 23, Issue 10, pp 805–815

Seizures in Patients with Multiple Sclerosis

Epidemiology, Pathophysiology and Management
Therapy in Practice

Abstract

Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.

The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.

Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.

References

  1. 1.
    Leube W. Ueber multiple inselförmige Sklerose des Gehirns und Rückenmarks: Nach Beobachtungen aus der Erlanger medicinischen Klinik. Dtsch Arch Klin Med 1871; 8: 1–29Google Scholar
  2. 2.
    Ross J. A treatise on the diseases of the nervous system. 2nd ed. London: J & A Churchill, 1883Google Scholar
  3. 3.
    Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 2004 Jun; 106(3): 147–58PubMedCrossRefGoogle Scholar
  4. 4.
    Hoefer P, Guttman S. The electroencephalogram in multiple sclerosis. Trans Am Neurol Assoc 1944; 70: 70–3Google Scholar
  5. 5.
    Muller R. Studies on disseminated sclerosis with special reference to symptomatology, course and prognosis. Acta Med Scand 1949; 133 Suppl. 222: 1–214Google Scholar
  6. 6.
    Fuglsang-Frederiksen V, Thygesen P. Seizures and psychopathology in multiple sclerosis. Acta Psychiatr Neurol Scand 1952; 27(1–2): 17–41PubMedCrossRefGoogle Scholar
  7. 7.
    Williams Jr GH, Nosik WA, Hunter Jr JA. Convulsions as manifestation of multiple sclerosis. JAMA 1952 Nov 8; 150(10): 990–2CrossRefGoogle Scholar
  8. 8.
    Feldman S. Convulsions in multiple sclerosis. J Nerv Ment Dis 1957 Apr–Jun; 125(2): 213–20PubMedCrossRefGoogle Scholar
  9. 9.
    Drake Jr WE, Macrae D. Epilepsy in multiple sclerosis. Neurology 1961 Sep; 11: 810–6PubMedCrossRefGoogle Scholar
  10. 10.
    Matthews WB. Epilepsy and disseminated sclerosis. Q J Med 1962 Apr; 31: 141–55PubMedGoogle Scholar
  11. 11.
    Poser CM. Clinical diagnostic criteria in epidemiological studies of multiple sclerosis. Ann NY Acad Sci 1965 Mar 31; 122: 506–19PubMedCrossRefGoogle Scholar
  12. 12.
    Oftedal SI. Multiple sclerosis in Vestfold, Norway. Acta Med Scand 1966; 42 Suppl. 19: 19–26Google Scholar
  13. 13.
    Hopf HC, Stamatovic AM, Wahren W. Cerebral seizures in multiple sclerosis [in German]. Z Neurol 1970; 198(3): 256–79PubMedCrossRefGoogle Scholar
  14. 14.
    Cendrowski W, Majkowski J. Epilepsy in multiple sclerosis. J Neurol Sci 1972 Dec; 17(4): 389–98PubMedCrossRefGoogle Scholar
  15. 15.
    Trouillas P, Courjon J. Epilepsy with multiple sclerosis. Epilepsia 1972 Apr; 13(2): 325–33PubMedCrossRefGoogle Scholar
  16. 16.
    Ritter G, Poser S. Epilepsy and multiple sclerosis (author’s transl.) [in German]. MMW Munch Med Wochenschr 1974 Nov 8; 116(45): 1983–6PubMedGoogle Scholar
  17. 17.
    Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 1981 Feb; 49(2): 253–71PubMedCrossRefGoogle Scholar
  18. 18.
    Granieri E, Rosati G, Tola R, et al. A descriptive study of epilepsy in the district of Copparo, Italy, 1964–1978. Epilepsia 1983 Aug; 24(4): 502–14PubMedCrossRefGoogle Scholar
  19. 19.
    Engelsen BA, Gronning M. Epileptic seizures in patients with multiple sclerosis: is the prognosis of epilepsy underestimated? Seizure 1997 Oct; 6(5): 377–82PubMedCrossRefGoogle Scholar
  20. 20.
    Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler 2002 Dec; 8(6): 495–9PubMedCrossRefGoogle Scholar
  21. 21.
    Kinnunen E, Wikström J. Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia 1986 Nov–Dec; 27(6): 729–33PubMedCrossRefGoogle Scholar
  22. 22.
    Nicoletti A, Sofia V, Biondi R, et al. Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia 2003 Nov; 44(11): 1445–8PubMedCrossRefGoogle Scholar
  23. 23.
    Nyquist PA, Cascino GD, McClelland RL, et al. Incidence of seizures in patients with multiple sclerosis: a population-based study. Mayo Clin Proc 2002 Sep; 77(9): 910–2PubMedGoogle Scholar
  24. 24.
    Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia 1999 Jun; 40(6): 745–7PubMedCrossRefGoogle Scholar
  25. 25.
    Muller J, Templin A, Sauermann W. Epileptic seizures in multiple sclerosis. Psychiatr Neurol Med Psychol 1986 Sep; 38(9): 497–502Google Scholar
  26. 26.
    Buttner T, Hornig CR, Dorndorf W. Multiple sclerosis and epilepsy: an analysis of 14 case histories [in German]. Der Nervenarzt 1989 May; 60(5): 262–7PubMedGoogle Scholar
  27. 27.
    Ghezzi A, Montanini R, Basso PF, et al. Epilepsy in multiple sclerosis. Eur Neurol 1990; 30(4): 218–23PubMedCrossRefGoogle Scholar
  28. 28.
    Moreau T, Sochurkova D, Lemesle M, et al. Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia 1998 Aug; 39(8): 893–6PubMedCrossRefGoogle Scholar
  29. 29.
    Sokic DV, Stojsavljevic N, Drulovic J, et al. Seizures in multiple sclerosis. Epilepsia 2001 Jan; 42(1): 72–9PubMedCrossRefGoogle Scholar
  30. 30.
    Striano P, Orefice G, Brescia Morra V, et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci 2003 Dec; 24(5): 322–8PubMedCrossRefGoogle Scholar
  31. 31.
    Gambardella A, Valentino P, Labate A, et al. Temporal lobe epilepsy as a unique manifestation of multiple sclerosis. Can J Neurol Sci 2003 Aug; 30(3): 228–32PubMedGoogle Scholar
  32. 32.
    Giuliani G, Terziani S, Senigaglia AR, et al. Epilepsy in an Italian community as assessed by a survey for prescriptions of antiepileptic drugs: epidemiology and patterns of care. Acta Med Scand 1992 Jan; 85(1): 23–31Google Scholar
  33. 33.
    Shiraishi K, Higuchi Y, Ozawa K, et al. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. Brain Dev 2005 Apr; 27(3): 224–7PubMedCrossRefGoogle Scholar
  34. 34.
    Ozakbas S, Idiman E, Baklan B, et al. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. Brain Dev 2003 Jun; 25(4): 233–6PubMedCrossRefGoogle Scholar
  35. 35.
    Gusev E, Boiko A, Bikova O, et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002 Jul; 104(3): 203–7PubMedCrossRefGoogle Scholar
  36. 36.
    Brass SD, Caramanos Z, Santos C, et al. Multiple sclerosis versus acute disseminated encephalomyelitis in childhood. Ped Neurol 2003 Sep; 29(3): 227–31CrossRefGoogle Scholar
  37. 37.
    US FDA. Avonex packaging insert [online]. Available from URL: http://www.fda.gov/CDER/foi/label/2003/ifnbbio013103LB.pdf [Accessed 2009 Jan 28]
  38. 38.
    US FDA. Rebif packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/ifnbser050203LB.pdf [Accessed 2009 Jan 28]
  39. 39.
    US FDA. Betaseron packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/ifnbchi031403LB.pdf [Accessed 2009 Jan 28]
  40. 40.
    US FDA. Copaxone packaging insert [online]. Available from URL: http://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf [Accessed 2009 Jan 28]
  41. 41.
    Mares P, Tabashidze N. Contradictory effects of GABA-B receptor agonists on cortical epileptic afterdischarges in immature rats. Brain Res Bull 2008 Jan 31; 75(1): 173–8PubMedCrossRefGoogle Scholar
  42. 42.
    Leung NY, Whyte IM, Isbister GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas 2006 Feb; 18(1): 77–82PubMedCrossRefGoogle Scholar
  43. 43.
    Peng CT, Ger J, Yang CC, et al. Prolonged severe withdrawal symptoms after acute-on-chronic baclofen overdose. J Toxicol 1998; 36(4): 359–63Google Scholar
  44. 44.
    Schuele SU, Kellinghaus C, Shook SJ, et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005 Mar 22; 64(6): 1086–7PubMedCrossRefGoogle Scholar
  45. 45.
    Zak R, Solomon G, Petito F, et al. Baclofen-induced generalized nonconvulsive status epilepticus. Ann Neurol 1994 Jul; 36(1): 113–4PubMedCrossRefGoogle Scholar
  46. 46.
    Bever Jr CT, Anderson PA, Leslie J, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996 Dec; 47(6): 1457–62PubMedCrossRefGoogle Scholar
  47. 47.
    Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008 Oct 7; 71(15): 1134–41PubMedCrossRefGoogle Scholar
  48. 48.
    Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007 Apr; 13(3): 357–68PubMedCrossRefGoogle Scholar
  49. 49.
    Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother 2008 Oct; 42(10): 1458–65PubMedCrossRefGoogle Scholar
  50. 50.
    Solari A, Uitdehaag B, Giuliani G, et al. Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD001330Google Scholar
  51. 51.
    Truyen L, Barkhof F, Frequin ST, et al. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler 1996 Feb; 1(4): 213–7Google Scholar
  52. 52.
    Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009 Feb 28; 373(9665): 732–8PubMedCrossRefGoogle Scholar
  53. 53.
    Goodman AD, Brown TR, Cohen JA, et al. Fampridine MS-F202 Study Group: dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008 Oct 7; 71(15): 1134–41PubMedCrossRefGoogle Scholar
  54. 54.
    Primavera A, Gianelli MV, Bandini F. Aphasic status epilepticus in multiple sclerosis. Eur Neurol 1996; 36(6): 374–7PubMedCrossRefGoogle Scholar
  55. 55.
    Newman P, Saunders M. A unique case of musicogenic epilepsy. Arch Neurol 1980 Apr; 37(4): 244–5PubMedCrossRefGoogle Scholar
  56. 56.
    Striano P, Striano S, Carrieri PB, et al. Epilepsia partialis continua as a first symptom of multiple sclerosis: electrophysiological study of one case. Mult Scler 2003 Mar; 9(2): 199–203PubMedCrossRefGoogle Scholar
  57. 57.
    Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin Proc 2001 Oct; 76(10): 983–6PubMedCrossRefGoogle Scholar
  58. 58.
    Thompson AJ, Kermode AG, Moseley IF, et al. Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry 1993 Dec; 56(12): 1317–20PubMedCrossRefGoogle Scholar
  59. 59.
    Calabrese M, De Stefano N, Atzori M, et al. Extensive cortical inflammation is associated with epilepsy in multiple sclerosis. J Neurol 2008 Apr; 255(4): 581–6PubMedCrossRefGoogle Scholar
  60. 60.
    Awerbuch GI, Verma NP. Periodic lateralized epileptiform discharges in a patient with definite multiple sclerosis. Clin EEG 1987 Jan; 18(1): 38–40Google Scholar
  61. 61.
    Chabolla DR, Moore JL, Westmoreland BF. Periodic lateralized epileptiform discharges in multiple sclerosis. Electroencephalogr Clin Neurophysiol 1996 Jan; 98(1): 5–8PubMedCrossRefGoogle Scholar
  62. 62.
    Gandelman-Marton R, Rabey JM, Flechter S. Periodic lateralized epileptiform discharges in multiple sclerosis: a case report. J Clin Neurophysiol 2003 Apr; 20(2): 117–21PubMedCrossRefGoogle Scholar
  63. 63.
    Kidd D, Barkhof F, McConnell R, et al. Cortical lesions in multiple sclerosis. Brain 1999 Jan; 122 (Pt 1): 17–26PubMedCrossRefGoogle Scholar
  64. 64.
    Geurts JJ, Bo L, Pouwels PJ, et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005 Mar; 26(3): 572–7PubMedGoogle Scholar
  65. 65.
    Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005 Nov; 128 (Pt 11): 2705–12PubMedCrossRefGoogle Scholar
  66. 66.
    Pirko I, Lucchinetti CF, Sriram S, et al. Gray matter involvement in multiple sclerosis. Neurology 2007 Feb 27; 68(9): 634–42PubMedCrossRefGoogle Scholar
  67. 67.
    Stadelmann C, Albert M, Wegner C, et al. Cortical pathology in multiple sclerosis. Curr Op Neurol 2008 Jun; 21(3): 229–34CrossRefGoogle Scholar
  68. 68.
    Zarei M. Clinical characteristics of cortical multiple sclerosis. J Neurol Sci 2006 Jun 15; 245(1–2): 53–8PubMedCrossRefGoogle Scholar
  69. 69.
    Zarei M, Chandran S, Compston A, et al. Cognitive presentation of multiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg Psychiatry 2003 Jul; 74(7): 872–7PubMedCrossRefGoogle Scholar
  70. 70.
    Kahana E, Leibowitz U, Alter M. Cerebral multiple sclerosis. Neurology 1971 Dec; 21(12): 1179–85PubMedCrossRefGoogle Scholar
  71. 71.
    Calabrese M, Atzori M, Bernardi V, et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007 Sep; 254(9): 1212–20PubMedCrossRefGoogle Scholar
  72. 72.
    Boggild MD, Williams R, Haq N, et al. Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosis. Neuroradiology 1996 May; 38Suppl. 1: S10–3PubMedCrossRefGoogle Scholar
  73. 73.
    Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007 Oct; 64(10): 1416–22PubMedCrossRefGoogle Scholar
  74. 74.
    Kangarlu A, Bourekas EC, Ray-Chaudhury A, et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007 Feb; 28(2): 262–6PubMedGoogle Scholar
  75. 75.
    Zivadinov R, Stosic M, Cox JL, et al. The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 2008 Mar; 255 Suppl. 1: 61–74CrossRefGoogle Scholar
  76. 76.
    Slapo GD, Lossius MI, Gjerstad L. Poststroke epilepsy: occurrence, predictors and treatment. Expert Rev Neurother 2006 Dec; 6(12): 1801–9PubMedCrossRefGoogle Scholar
  77. 77.
    Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia 2008 Aug; 49Suppl. 6: 13–8PubMedCrossRefGoogle Scholar
  78. 78.
    Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 2006 May; 47(5): 867–72PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of CincinnatiCincinnatiUSA
  2. 2.Department of Neurology, Mayo ClinicRochesterUSA

Personalised recommendations